Centessa Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Mario Accardi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 0.1% |
| Management average tenure | 1.6yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Oct 28
Centessa Pharmaceuticals (NASDAQ:CNTA) Is Using Debt Safely
Jul 17Is There An Opportunity With Centessa Pharmaceuticals plc's (NASDAQ:CNTA) 50% Undervaluation?
Apr 19Does Centessa Pharmaceuticals (NASDAQ:CNTA) Have A Healthy Balance Sheet?
Mar 15Are Investors Undervaluing Centessa Pharmaceuticals plc (NASDAQ:CNTA) By 30%?
Jan 02Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring
Dec 31Is Centessa Pharmaceuticals (NASDAQ:CNTA) Using Debt Sensibly?
Nov 14Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B
Sep 25Centessa Pharmaceuticals (NASDAQ:CNTA) Has Debt But No Earnings; Should You Worry?
Aug 15Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Apr 24Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Mar 07Centessa Pharmaceuticals snaps multi-day losing streak; up 10%
Oct 20Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
Sep 14Centessa Pharmaceuticals GAAP EPS of -$0.69
Aug 10Checking In On Centessa Pharmaceuticals
Dec 23CEO
Mario Accardi
Dr. Mario Alberto Accardi, Ph D., MENG, is Co-Founder, Chairman & Director of Orthonika Limited. He was CEO of Orthonika Limited.He served as President of the Orexin Program at Centessa Pharmaceuticals pl...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Principal Financial Officer | 1.6yrs | US$4.35m | no data | |
| General Counsel | 4.9yrs | US$2.05m | 0.027% $ 985.2k | |
| CEO & Director | no data | no data | 0.12% $ 4.4m | |
| Chief Accounting Officer & Principal Accounting Officer | less than a year | no data | no data | |
| Chief Technology & Quality Officer | 2.8yrs | no data | 0.051% $ 1.8m | |
| Senior Vice President of Investor Relations & Corporate Communications | 3.6yrs | no data | no data | |
| Chief People Officer | 3.2yrs | no data | 0.040% $ 1.4m | |
| Chief Business Officer | 1.6yrs | US$3.31m | 0.041% $ 1.5m | |
| Senior Vice President of Clinical Development Operations | 1.3yrs | no data | no data | |
| Head of R&D and Chief Medical Officer | 1yr | no data | no data | |
| Senior Vice President of Regulatory Affairs & Medical Writing | 1yr | no data | no data |
Experienced Management: CNTA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | no data | 0.12% $ 4.4m | |
| Independent Non-Executive Chairman of the Board | 5.2yrs | no data | no data | |
| Independent Non-Executive Director | 4.9yrs | US$252.69k | 0% $ 0 | |
| Independent Non-Executive Director | 5yrs | US$257.69k | 0% $ 0 | |
| Independent Director | 5yrs | US$26.25k | no data | |
| Independent Non-Executive Director | 5yrs | US$260.19k | 0.32% $ 11.4m | |
| Independent Non-Executive Director | 4.9yrs | US$255.19k | 0% $ 0 | |
| Independent Non-Executive Director | 4.7yrs | US$262.69k | 0% $ 0 | |
| Independent Non-Executive Director | 3.5yrs | US$247.69k | 0% $ 0 |
Experienced Board: CNTA's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 11:52 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Centessa Pharmaceuticals plc is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |